Feedback / Questions
CRB-913 - Corbus Pharma
https://www.globenewswire.com/news-release/2025/03/28/3051321/0/en/Corbus-Pharmaceuticals-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Study-of-Next-Generation-CB1-Inverse-Agonist-CRB-913-for-the-Treatment-of-Obesity.html
Mar 28, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next